Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer - PubMed (original) (raw)
. 1999 Nov;180(5):1415-23.
doi: 10.1086/315086.
Affiliations
- PMID: 10515798
- DOI: 10.1086/315086
Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer
E L Franco et al. J Infect Dis. 1999 Nov.
Abstract
Acquisition and clearance of cervical human papillomavirus (HPV) infection were analyzed among 1425 low-income women attending a maternal and child health program in São Paulo, Brazil. Specimens collected every 4 months were tested by a polymerase chain reaction protocol (MY09/11). In all, 357 subjects were positive at least once. There were 1.3% new infections per month, with 38% cumulative positivity after 18 months. Of 177 positive subjects at enrollment, only 35% remained infected after 12 months. The monthly clearance rate was higher for nononcogenic types (12.2%; 95% confidence interval [CI], 9.6-15.4) than for oncogenic HPV infections (9.5%; 95% CI, 7.5-11.9). Median retention times were 8.1 months (95% CI, 7.8-8.3) for oncogenic types and 4.8 months (95% CI, 3.9-5.6) for nononcogenic HPV infections. The mean infection durations were 8.2 and 13.5 months for nononcogenic and oncogenic types, respectively. Although a woman's age did not affect mean duration for oncogenic types (13-14 months), nononcogenic-type infections lasted longer (10. 2 months) among younger (<35 years old) than in older women (5.6 months).
Similar articles
- Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study.
Giuliano AR, Harris R, Sedjo RL, Baldwin S, Roe D, Papenfuss MR, Abrahamsen M, Inserra P, Olvera S, Hatch K. Giuliano AR, et al. J Infect Dis. 2002 Aug 15;186(4):462-9. doi: 10.1086/341782. Epub 2002 Aug 2. J Infect Dis. 2002. PMID: 12195372 - A cumulative case-control study of risk factor profiles for oncogenic and nononcogenic cervical human papillomavirus infections.
Rousseau MC, Franco EL, Villa LL, Sobrinho JP, Termini L, Prado JM, Rohan TE. Rousseau MC, et al. Cancer Epidemiol Biomarkers Prev. 2000 May;9(5):469-76. Cancer Epidemiol Biomarkers Prev. 2000. PMID: 10815691 - Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women.
Palefsky JM, Holly EA, Ralston ML, Da Costa M, Greenblatt RM. Palefsky JM, et al. J Infect Dis. 2001 Feb 1;183(3):383-91. doi: 10.1086/318071. Epub 2000 Dec 29. J Infect Dis. 2001. PMID: 11133369 - [Genital infection with human papillomavirus (HPV): viral screening and typing, importance of in situ hybridization].
Walker F, Darai E, Dauge-Geffroy MC, Joannes M, Soustre E, Lehy T, Potet F. Walker F, et al. Ann Pathol. 1996 Nov;16(5):364-73. Ann Pathol. 1996. PMID: 9004724 Review. French. No abstract available. - [Cervical pathology and immunodepression].
Quéreux C, Hourdequin P, Saniez D, Rémy G. Quéreux C, et al. Contracept Fertil Sex. 1994 Dec;22(12):771-6. Contracept Fertil Sex. 1994. PMID: 7827639 Review. French.
Cited by
- Global pattern of persistent human papillomavirus infection in female genital tract: An update system review and meta-analysis.
Zhao M, Kang P, Zhu L, Zhou D, Cui M, Zhang M, Jia J, Luo L. Zhao M, et al. iScience. 2024 Sep 19;27(10):110991. doi: 10.1016/j.isci.2024.110991. eCollection 2024 Oct 18. iScience. 2024. PMID: 39474077 Free PMC article. - Skin Lesions Caused by HPV-A Comprehensive Review.
Maghiar L, Sandor M, Sachelarie L, Bodog R, Huniadi A. Maghiar L, et al. Biomedicines. 2024 Sep 13;12(9):2098. doi: 10.3390/biomedicines12092098. Biomedicines. 2024. PMID: 39335611 Free PMC article. Review. - Will methylation assays be part of a full molecular strategy to improve clinical management of cervical neoplasia?
El-Zein M, Franco EL. El-Zein M, et al. Epigenomics. 2024;16(18):1197-1201. doi: 10.1080/17501911.2024.2402684. Epub 2024 Sep 25. Epigenomics. 2024. PMID: 39320908 No abstract available. - Advances in Targeted Therapy for the Treatment of Cervical Cancer.
Watkins DE, Craig DJ, Vellani SD, Hegazi A, Fredrickson KJ, Walter A, Stanbery L, Nemunaitis J. Watkins DE, et al. J Clin Med. 2023 Sep 15;12(18):5992. doi: 10.3390/jcm12185992. J Clin Med. 2023. PMID: 37762931 Free PMC article. Review. - Prevalence of Human Papillomavirus in Different Mucous Membranes in HIV Concordant Couples in Rwanda.
Uwamungu S, Nigussie B, Muvunyi CM, Hasséus B, Andersson M, Giglio D. Uwamungu S, et al. Viruses. 2023 Apr 19;15(4):1005. doi: 10.3390/v15041005. Viruses. 2023. PMID: 37112984 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical